人类恶性疾病疫苗治疗中的树突状细胞。

Dendritic cells in vaccination therapies of human malignant disease.

作者信息

Reichardt Volker L, Brossart Peter, Kanz Lothar

机构信息

Department of Hematology, Oncology, Immunology and Rheumatology, University of Tübingen, Otfried-Müller Str. 10, D-72076 Tübingen, Germany.

出版信息

Blood Rev. 2004 Dec;18(4):235-43. doi: 10.1016/j.blre.2003.12.001.

DOI:10.1016/j.blre.2003.12.001

PMID:15501552

Abstract

Dendritic cells (DC) are the most efficient antigen presenting cells in various in vitro systems and DC are now introduced to early clinical use. Tumor antigen loaded DC might potentially add therapeutic benefit with dendritic cell based vaccination. This review will focus on dendritic cell biology relevant to investigators who work in transitional research programs and will discuss the rationale of DC source, antigen loading and route of vaccination. An overview of published and on-going clinical trials in human malignant diseases will be provided forming the basis for a discussion of perspectives of dendritic cell vaccination in various human malignancies.

摘要

树突状细胞（DC）是各种体外系统中最有效的抗原呈递细胞，目前已被引入早期临床应用。负载肿瘤抗原的DC可能通过基于树突状细胞的疫苗接种带来治疗益处。本综述将聚焦于与从事转化研究项目的研究人员相关的树突状细胞生物学，并将讨论DC来源、抗原负载和疫苗接种途径的基本原理。将提供已发表和正在进行的人类恶性疾病临床试验的概述，为讨论树突状细胞疫苗接种在各种人类恶性肿瘤中的前景奠定基础。